Neurofilament light chain (NFL) and chitinase-3-like-1 (CHI3L1) concentrations in cerebrospinal fluid (CSF) may have prognostic value in clinically isolated syndromes (CIS) and relapsing–remitting multiple sclerosis (RRMS).
Objectives:
To compare the prognostic value of CSF concentrations of NFL and CHI3L1 in newly diagnosed CIS and RRMS patients.
Methods:
NFL and CHI3L1 were measured in CSF in 177 newly diagnosed patients with CIS or RRMS who were followed clinically for a mean of 5.7 years.
Results:
At baseline CSF concentrations of NFL correlated with CSF concentrations of CHI3L1, relapses in the previous year, time from last relapse, and the Expanded Disability Status Scale (EDSS) score. CSF concentrations of NFL and CHI3L1 were both associated with increased relapse risk during the first 2 years in univariate analyses, but only the CSF concentration of NFL was independently associated with relapse risk in a multivariable analysis. There was no relationship between CSF concentrations of NFL or CHI3L1 and risk of conversion to secondary progressive MS or development of disability.
Conclusion:
CSF concentrations of NFL are associated with 2-year relapse risk but not with disease progression or clinical worsening in newly diagnosed CIS and RRMS patients. This may be due to confounding by the effect of disease-modifying therapies.
BrownMGKirbySSkedgelC, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?Neurology2007; 69: 1498–1507.
5.
ShiraniAZhaoYKarimME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA2012; 308: 247–256.
6.
TedeholmHLyckeJSkoogB, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler2013; 19: 765–774.
7.
TrojanoMPellegriniFFuianiA, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol2007; 61: 300–306.
8.
HartungHPGonsetteRKonigN, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002; 360: 2018–2025.
9.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
10.
EdanGComiGLePE, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: A 3-year randomised trial. J Neurol Neurosurg Psychiatry2011; 82: 1344–1350.
11.
ArrambideGEspejoCEixarchH, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology2016; 87: 1076–1084.
12.
CantoETintoreMVillarLM, et al. Chitinase 3-like 1: Prognostic biomarker in clinically isolated syndromes. Brain2015; 138: 918–931.
13.
ComabellaMFernandezMMartinR, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain2010; 133: 1082–1093.
14.
ModvigSDegnMRoedH, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler2015; 21: 1761–1770.
15.
SalzerJSvenningssonASundstromP.Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler2010; 16: 287–292.
16.
HakanssonITisellACasselP, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol2017; 24: 703–712.
17.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121–127.
18.
OturaiABKoch-HenriksenNPetersenT, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol2009; 16: 420–423.
19.
SellebjergFChristiansenM.Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: Interlaboratory reproducibility and interobserver agreement. Scand J Clin Lab Invest1996; 56: 135–143.
20.
KuhleJPlattnerKBestwickJP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler2013; 19: 1597–1603.
21.
HogdallEVJohansenJSKjaerSK, et al. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest2000; 60: 247–251.
22.
JessenKJMellbergTPriceRW, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS ONE2014; 9: e88591.
23.
BarkhofFRoccaMFrancisG, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol2003; 53: 718–724.
24.
GunnarssonMMalmestromCAxelssonM, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol2011; 69: 83–89.
25.
De FlonPGunnarssonMLaurellK, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology2016; 87: 141–147.
26.
NovakovaLAxelssonMKhademiM, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem2017; 141: 296–304.
27.
KomoriMKosaPSteinJ, et al. Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol2017; 4: 478–490.
28.
PiehlFKockumIKhademiM, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler2018; 24: 1046–1054.
29.
DisantoGBarroCBenkertP, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81: 857–870.
30.
KuhleJBarroCAndreassonU, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med2016; 54: 1655–1661.
31.
SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol2013; 12: 669–676.
32.
FisnikuLKBrexPAAltmannDR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
